|

Efgartigimod PH20 SC Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 2/3: 1

Top Sponsors

  • argenx1

Indications

  • Generalized Myasthenia Gravis1
  • Cancer1

Charlotte, North Carolina1 trial

A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis

Carolinas HealthCare System Neurosciences Institute - Neurology

Phase 2/3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.